Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You're right. This is not an all or nothing presentation of our opportunity.
But I've seen reasons to support those possibilities. I believe they are all real. Whatever we don't announce within the next two days, I hope will be announced as we move back to Nasdaq.
I don't see how we could:
Miss getting the continuation decision by the Data and Safety Monitoring Board in the Acute Graft versus Host Disease trial;
Miss being the drug used in the Novavax prototype covid vaccine, which caused European regulators to request more data, and which may have shut down the NVAX shareholders' lawsuit claiming that there was no effective prototype vaccine. The prototype vaccine had to go through a clinical trial, unlike the updated vaccine, which was approved based on non-clinical trial data;
Miss getting EUL or EUA authorization for covid which, if obtained, will open up our market to the prophylaxis use of lenz as a vaccine adjuvant, in addition to the therapeutic use to treat infected patients;
Miss getting an expedited approval to treat CMML from the Australian government, complete with a possible $100M+ Priority Review Voucher;
Miss executing the recall of our loaned shares, which I think will be the biggest ever seen, and will make millionaires of some of us who already have every share of Humanigen stock we have been able to buy;
Miss a business restructuring that will lead the way back to the Nasdaq, with partners who will be handling our distribution and commercialization as they use lenz to strengthen the safety and efficacy of their own products and platforms, such as CAR-T;
Miss saving the lives of millions of people worldwide, who will only suffer preventable deaths under existing standard of care, especially if a new covid variant begins circulating that it far stronger and transmissible than any previous variant;
Miss preventing trillions of dollars in damage to the worldwide economies and societies.
Thank you for asking. And thank management for their steadfast effort to make this happen.
You could be right, Tank, although I would be very surprised that an auditor would sign-off on a 10-K when we have two delinquent 10-Q's. But, one paragraph in each Q, concerning the Baudax/Tera-Immune transaction initiation, and completion, could have both filings made ready.
https://www.sec.gov/Archives/edgar/data/1178179/000101359423000580/baudax13ga1-07102023.htm
I just don't see how we could miss.
Thank you, Newtg.
I was aware of the distinction your source noted.
But rather than, "Two things going on here," I suspect that there may be three things going on.
Share with your source, please, the clinicaltrials.gov site, regarding the C-SMART trial, referenced in the following post.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173360982
I found this:
https://clinicaltrials.gov/study/NCT04534725?term=NCT04534725&rank=1
I wonder if lenzilumab's enhancement of the Novavax prototype vaccine led to the settlement of the litigation against Novavax in this regard, which read as follows:
Novavax, "...made certain purportedly false and misleading statements concerning the Company’s ability to manufacture prototype vaccine on a commercial scale and to secure the prototype vaccine’s regulatory approval."
https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000110465923123481/tm2332186d1_8k.htm
Dr. Daniel Thomas, one of the investigators in our CMML trial, will be moderating our presentation at the ASH Conference on Saturday, discussing the Complete Remission rates those cancer patients achieved with lenz.
"1852 Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia."
https://ash.confex.com/ash/2023/webprogram/Paper179706.html
This is in stark contrast to what Gilead achieved using magrolimab.
"Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS"
https://www.gilead.com/news-and-press/press-room/press-releases/2023/7/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds
And of course, since our results were already published in the 'blood' journal, our presentation should be well-received.
https://ashpublications.org/blood/article/142/Supplement%201/1847/505640/Lenzilumab-in-Addition-to-Azacitidine-Improves
In addition, we know that this indication offered certain regulatory incentives. Will our demonstrated success result in an expedited approval or the award of a Priority Review Voucher? If so, will Humanigen announce that news this week, ahead of the conference, and perhaps with the announcement of the recall of our loaned shares?
Also, I see that another of our trial doctors, Dr. Saad Kenderian, who was also very excited about lenzilumab's performance in the LIVE-AIR trial, will also be moderating a separate presentation on Immunotherapies.
https://ash.confex.com/ash/2023/webprogram/Session24628.html
I hope shareholders can begin to see the long-awaited benefit of our faith In Humanigen, and in lenzilumab. It certainly looks promising.
Newtg, I can't help but notice that the link you provided indicates there was an update on Nov 30th, which was the date of your post.
"COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; C-SMART study Arm 4: Effect of Lenzilumab in cancer patients with severe COVID-19 infection.
Up to date
(Last updated: 30/11/2023)"
https://www.anzctr.org.au/TrialSearch.aspx#&&conditionCode=&dateOfRegistrationFrom=&interventionDescription=&interventionCodeOperator=OR&primarySponsorType=&gender=&distance=&postcode=&pageSize=20&ageGroup=&recruitmentCountryOperator=OR&recruitmentRegion=ðicsReview=&countryOfRecruitment=®istry=&searchTxt=Lenzilumab&studyType=&allocationToIntervention=&dateOfRegistrationTo=&recruitmentStatus=&interventionCode=&healthCondition=&healthyVolunteers=&page=1&conditionCategory=&fundingSource=&trialStartDateTo=&trialStartDateFrom=&phase=
But the trial review indicates:
Recruitment status Withdrawn
Reason for early stopping/withdrawal Lack of funding/staff/facilities
Participant recruitment difficulties
However, in checking the NIH National Library of Medicine site, I see the status of the trial is "Completed," and that actual enrollment was 441 participants.
https://clinicaltrials.gov/study/NCT04534725
I've looked at the few other boards I have access to, and don't see anything about this. I assume, therefore, that this info was provided on an "invite only" board.
Wherever it came from, could you share this post there, and see if the posters can provide some guidance in this regard? I can't figure it out. What I see looks contradictory.
Thank you!
The Hydrogenone chart continues to display on our ShortVolumes.com site.
http://shortvolumes.com/?t=HGEN
We do have a London subsidiary.
https://www.humanigen.com/subsidiaries
So is this signifying a connection between the companies? Are we in an ETF with them? Or is this just an uncorrected display?
I think the only Bufferin that could be required would be for Durrant, trying to satisfy parties of interest to this filing.
I think it's a static sight, and there is no data compilation needed, so buffering is not an applicable consideration.
Here's a link to the site.
https://www.sec.gov/cgi-bin/browse-edgar?company=humanigen&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
I've been monitoring this site several times each day, for multiple companies, for many years. I've never seen anything like this before.
As our latest Form 4 continues to disappear and reappear, even this morning, we may need to consider who the beneficiary of these shares may be. Baudax is still a contender. But another possibility may be that Novavax will receive these shares in a stock-for-stock merger agreement.
I say that for two new reasons. First, Novavax announced approval of their standard vaccine in South Korea just days ago.
https://ir.novavax.com/press-releases/Novavaxs-Updated-COVID-19-Vaccine-Receives-Emergency-Use-Authorization-in-the-Republic-of-Korea
And we know that S. Korea conducted a safety trial of Humanigen's lenzilumab some time ago.
https://ir.humanigen.com/English/news/news-details/2021/Humanigens-Partner-in-South-Korea-Receives-Ministry-of-Food-and-Drug-Safety-MFDS-Approval-to-Conduct-Phase-1-Study-of-Lenzilumab/default.aspx
In addition, the WHO's Emergency Use Listing (EUL) approval of the standard Novavax vaccine was based on non-clinical data.
However, in regards to Novavax's prototype vaccine, "In clinical trials, the most common adverse reactions associated with Novavax's prototype COVID-19 vaccine (NVX-CoV2373) included headache, nausea or vomiting, muscle pain, joint pain, injection site tenderness, injection site pain, fatigue and malaise." It would likely have been the prototype vaccine that used lenz as an adjuvant.
It would be very exciting to see news in this regard, if my assumption about incorporating lenz in the prototype vaccine is correct.
I can't find the specific post I need to clarify the status of the various trials, but I found something close. I believe the person I contacted was with the IMPACT group, conducting the RATinG study of aGvHD.
"IMPACT is going to do an interim assessment of the first 20 patients who get enrolled in their 18 treatment centers.
"The first stage of the trial is expected to treat 20 participants with lenzilumab before conducting an interim assessment of safety, efficacy, and feasibility."
https://ir.humanigen.com/English/news/news-details/2023/Humanigen-Announces-First-Participant-Dosed-in-RATinG-Trial-of-Lenzilumab-for-Early-Treatment-of-Acute-Graft-Versus-Host-Disease-Following-Allogeneic-Stem-Cell-Transplantation/default.aspx
So it may not take long for the data monitoring committee to collect and review data from 20 patients, from 18 sites, and making a recommendation to a second trial stage. Maybe we'll hear something about that CMML patient who progressed to needing aGvHD to be cured of his cancer."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172695604
So I hope we will hear more from this trial.
"And give that discretionary authority to the pharmaceutical companies to self regulate?"
Um, no. I think Self Regulatory Organizations (SRO's) should also be banned.
I totally agree with you, sosjtb, that, "...regulations exist for a reason..." And they should be enforced. There should be no discretionary authority invested in the offices of unelected bureaucrats to ignore the laws created by the elected legislators. NONE. These agencies should follow the laws, as written, unless the legislators change the law.
“As a seasonal slew of respiratory illnesses circulate, it’s Covid that continues to send the most people to the hospital, the Centers for Disease Control and Prevention said Friday.
Covid is still the primary cause of new respiratory virus hospitalizations and death,” CDC Director Dr. Mandy Cohen said at a briefing for reporters Friday.
The virus is responsible for about 15,000 hospitalizations and 1,000 deaths every week, she said."
https://www.yahoo.com/news/covid-drives-hospitalizations-across-country-120000797.html
How many of these hospitalizations and deaths will lenz and the lenz vaccine cocktail prevent? At the least, this is willful negligence by government regulators to approve lenz. Those who are personally benefitting by maintaining the status quo in regards to authorizations and approvals could be guilty of criminal negligence. This includes, but transcends, the remedy of medical license revocation. These people should be arrested, tried, and sentenced for their corruption.
We have got to rescind discretionary authority from government agencies.
I can see where Fauci should be allowed to practice medicine...at a Mens' Federal Medical Center prison.
For the first time since June, I'm seeing data reported by the 'Short Volumes' website regarding Humanigen's stock. For the last session, they reported, "The short sale volume percent (not short interest) for stock ticker HGEN is 68.45% on Dec 01, 2023. The short sale volume is 60,256. The total volume is 88,027. The short sale volume percent is up 68.29% compare to Nov 30, 2023."
http://shortvolumes.com/?t=HGEN
I don't know if Humanigen is providing 'locates' for these short positions, but being on the Expert Market, I don't know who else would. Is this preparatory for the recall of our loaned shares?
Also, the price chart displays data for Hydrogenome Capital Growth, which trades on the London exchange with the ticker HGEN.L. It should not be displayed on Humanigen's site.
In the event that the displayed data is removed, this is what is currently showing for the past 10 days.
The Volume and short volume are limited. It is not including all volumes from all Market.
Date Short Volume Total Volume Percent
2023-12-01 60,256 88,027 68.45%
2023-11-30 98 61,710 0.16%
2023-11-29 16,738 56,449 29.65%
2023-11-27 10 9,803 0.1%
2023-11-20 170 64,808 0.26%
2023-11-17 42,300 52,728 80.22%
2023-11-16 5,800 42,895 13.52%
2023-11-15 100 19,000 0.53%
2023-11-14 370 34,653 1.07%
2023-11-13 55,924 61,677 90.67%
Posters' opinions can be expected to be right or wrong. But it is definitely not nice for a reporting website to display inaccurate information that needlessly confuses an old man trying to maintain some semblance of his mental faculty. And yes, I resemble that remark.
I just hope the accurate portion of this data display portends the imminent recall of our loaned shares.
Interesting, isn't it, that the FDA cleared Gracell's 'GC012F' CAR-T IND application on Nov 27th, and then the next day, they announced that they were investigating the cancer risks linked to CAR-T therapy?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173299876
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173316333
Humanigen's latest patent, dated in June of this year, was to improve the, "Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
Patent number: 11673962..."
https://patents.justia.com/assignee/humanigen-inc
Is Gracell realizing the reduced toxicities achieved by using lenz in their CAR-T, as described in our patent? Has this opened the eyes of the FDA to the avoidable adverse consequences of other CAR-T's?
Is there hope that using lenz as a covid vaccine adjuvant, which Humanigen has also patented, is yielding the same success for the prototype Novavax vaccine?
Thanks for sharing this link, Tank. It was great to see this receive journal publication ahead of the ASH conference in regards to the PREACH-M study. Although I admit that I enjoyed Dr. Thomas' interviews far more on this subject. His excitement was contagious!
Newtg's article was in regards to lenzilumab representing the 4th arm of the C-SMART trial, which I think we pulled out of when the Australian government declared an end to the prioritization of covid trials.
I'm eagerly awaiting further updates on the aGvHD trial, after the first person was dosed and, as I recall, showed no continuing signs of CMML cancer.
for future reference:
https://ashpublications.org/blood/article/142/Supplement%201/1847/505640/Lenzilumab-in-Addition-to-Azacitidine-Improves
https://www.anzctr.org.au/TrialSearch.aspx#&&conditionCode=&dateOfRegistrationFrom=&interventionDescription=&interventionCodeOperator=OR&primarySponsorType=&gender=&distance=&postcode=&pageSize=20&ageGroup=&recruitmentCountryOperator=OR&recruitmentRegion=ðicsReview=&countryOfRecruitment=®istry=&searchTxt=Lenzilumab&studyType=&allocationToIntervention=&dateOfRegistrationTo=&recruitmentStatus=&interventionCode=&healthCondition=&healthyVolunteers=&page=1&conditionCategory=&fundingSource=&trialStartDateTo=&trialStartDateFrom=&phase=
"Pfizer is sued by Texas over COVID vaccine claims
Jonathan Stempel...
Updated Thu, November 30, 2023
(Reuters) - Pfizer has been sued by Texas Attorney General Ken Paxton, who on Thursday accused the drugmaker of misrepresenting the efficacy of its widely-used COVID-19 vaccine.
In a complaint filed in a Lubbock County state court, Paxton said it was misleading for Pfizer to claim its vaccine was 95% effective because it offered a "relative risk reduction" for people to who took it.
Paxton said the claim was based on only two months of clinical trial data, and vaccine recipients' "absolute risk reduction" showed that the vaccine was just 0.85% effective.
https://www.yahoo.com/news/pfizer-sued-texas-over-covid-204834093.html
There's a 30 degree temperature range forecasted here (Fort Worth, TX area) tomorrow, not too unusual. And Warren is only about 20 miles from my hometown of Youngstown, which I left after high school to join the Army.
But those temperature patterns have been consistent forever. I don't see any reason for those temperature ranges to all of a sudden be responsible for altering the human immune response system.
The best way to conduct biowarfare is to have your ignorant-ass targeted population further harm themselves with their own medical countermeasures. There's only so much you can alter the immune response system, before it is no longer capable of defending us. There's nothing common about a disease, or the treatments, that alters the immune response system.
I find it very suspicious that this phenomenon isn't being studied on a vaccinated vs unvaccinated basis.
"Ohio faces unprecedented child pneumonia outbreak
Brody Wooddell
Thu, November 30, 2023...
Health experts speculate that reduced exposure to common pathogens during the pandemic lockdowns might have weakened children’s immune systems, making them more susceptible to infections."
https://www.yahoo.com/news/ohio-faces-unprecedented-child-pneumonia-200617438.html
In the post-mass vaccination period, I think that any speculation about the weakened innate immune response system needs to compare patient populations on a vaccinated versus unvaccinated basis. I don't buy that the weakened immune response is due to reduced exposure to pathogens. I'd be interested in reading any studies that support that claim. I think it is more likely that the mRNA vaccines play a large role in altering the innate immune response.
As I have been writing this post, I see that 'Preciouslife1' has just shared a corroborating report from the NY Post regarding an outbreak of child pneumonia in Massachusetts. He provides the following link.
https://nypost.com/2023/12/01/news/massachusetts-records-child-pneumonia-outbreak-cases/
I can only hope that the Novavax prototype vaccine uses the lenz cocktail, and that this protein-based vaccine becomes standard of care in the 194 countries where Novavax is approved, and that we can avoid the self-destruction which only benefits the proponents of mRNA vaccines.
Well, this needs clarification. I know that I had read the Australian New Zealand trial registry you linked before. I may have even previously provided that same link. And I'm fairly certain that I had contacted Dr. Yong in this regard. Plus, I think I saw where Humanigen was no longer testing cancer patients with covid. If we don't get surprised with the announcement of the recall of our loaned shares, I'll look deeper into this.
Thank you, Newtg. As I recall, this trial was abandoned once the Australian government deemed that covid no longer posed a public health emergency to cancer patients. I may have even contacted Dr. Michelle Yong regarding this trial. I think management decided to focus on the PREACH-M trial, which looks like it may be the pathway to a cancer cure.
Mystery respiratory illness developing worldwide.
https://www.yahoo.com/news/dc-area-hospitals-see-uptick-213359373.html
Will these respiratory illnesses, which include pneumonia, progress to cytokine storm? Should we be prepared for that? Remember that lenz showed an 8-fold improvement in treatment outcomes for the Black and African American population.
"FDA investigating cancer risk linked to CAR-T cell therapy
Jonathan Gardner
Updated Tue, November 28, 2023"
https://www.yahoo.com/finance/news/fda-investigating-cancer-risk-linked-154600978.html
Can lenz improve the overall safety profile?
"WHO authorizes emergency use of Novavax's updated COVID shot
Reuters
Updated Tue, November 28, 2023"
https://www.yahoo.com/news/authorizes-emergency-novavaxs-updated-covid-112849432.html
I think authorization of Novavax's prototype vaccine is more relevant to us.
How ridiculous and uninformed it is to think that posting about other companies, whose platforms and drugs will benefit tremendously from lenz, have no bearing on this company. It's understandable that people may think that posting about other companies on this board doesn't belong here. But that only reflects a lack of appreciation of lenzilumab's capability. IN MY OPINION.
Tell that to Gilead, who tried to enhance azacitidine by acquiring '47 Inc.' for $4.9B, for their magrolimab MAB.
"Gilead to Acquire Forty Seven for $4.9 Billion"
https://www.gilead.com/news-and-press/press-room/press-releases/2020/3/gilead-to-acquire-forty-seven-for-49-billion
"Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS"
https://www.gilead.com/news-and-press/press-room/press-releases/2023/7/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds
And remember what Humanigen reported from the PREACH-M study of using lenz for CMML, versus Gilead's use of magrolimab.
"PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia"
https://www.news-medical.net/news/20230609/PREACH-M-trial-Lenzilumab-may-improve-treatment-response-in-chronic-myelomonocytic-leukemia.aspx
But you can certainly count me in on wanting to see, not just an update, but regulatory recognition and approval of lenz. The issue isn't that management owes us an update, it's that regulators, somewhere in the world, owe Humanigen authorization and approval of lenz.
"Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization...
NEWS PROVIDED BY
NOVAVAX, INC
28 Nov, 2023, 06:00 ET
The EUL was based on non-clinical data showing that Novavax's COVID-19 vaccine induced functional immune responses against XBB.1.5, XBB.1.16 and XBB.2.3 variants. Additional non-clinical data demonstrated that Novavax's vaccine induced neutralizing antibody responses to subvariants BA.2.86, EG.5.1, FL.1.5.1 and XBB.1.16.6 as well as CD4+ polyfunctional cellular (T-cell) responses against EG.5.1 and XBB.1.16.6. These data indicate Novavax's vaccine can stimulate both arms of the immune system and may induce a broad response against currently circulating variants.5,6
In clinical trials, the most common adverse reactions associated with Novavax's prototype COVID-19 vaccine (NVX-CoV2373) included headache, nausea or vomiting, muscle pain, joint pain, injection site tenderness, injection site pain, fatigue and malaise."
https://www.prnewswire.com/news-releases/novavaxs-updated-protein-based-covid-19-vaccine-now-an-option-for-all-194-member-states-of-the-world-health-organization-301998533.html
Again, I hope the prototype clinical trials are evaluating the use of the lenz cocktail.
The article stated that owners of 53% of shares in Xspray have declared their intention to exercise warrants. "The company’s Chairman, CEO and CFO have also declared the same intent." That doesn't suggest to me that all of the shareholders have been identified.
I mention this because the surreptitious control of an entity, through the exercise of warrants, was part of the news announced with the previous recall of our loaned shares. In addition, this company is where Ed Jordan is now the chief commercial officer. It's feasible that we will see that Humanigen has taken an ownership stake in the company, even if it doesn't amount to control.
https://xspraypharma.com/modular_finance_pressmeddelande/xspray-pharma-appoints-chief-commercial-officer-to-drive-upcoming-dasynoc-us-product-commercialization/
Lenz could prove to have a pivotal role in eliminating the black box warning for Xspray's nilotinib (TASIGNA) in the US.
https://xspraypharma.com/modular_finance_pressmeddelande/xspray-pharmas-xs003-achieves-superior-bioavailability-milestone-matching-tasigna-at-reduced-dosage/
"Gracell Biotechnologies Announces FDA Clearance of IND Application"
Look at the FDA Approvals section for ticker GRCL.
https://newsfilter.io/
"This progress marks the second U.S. IND clearance for GC012F, a notable milestone. As a next-generation CAR-T therapy, GC012F combines the innovative CD19/BCMA dual-targeting approach and our breakthrough FasTCAR next-day manufacturing technology, both of which could potentially provide meaningful benefits to SLE patients. Additionally, what sets GC012F apart is its consistently favorable safety profile demonstrated by the absence of neurotoxicity in 60 patients treated across three IIT studies. We look forward to developing GC012F as a transformative therapy for SLE patients, who are in urgent need of highly effective and safe treatment options."
Does lenz provide the enhanced safety and efficacy of this CAR-T therapy?
This would be a twist.
Promoting our first loaned shares recall, Humanigen announced a majority holder who assumed control by exercising warrants.
Cold we now see Humanigen announcing control of Xspray Pharma assumed by exercising warrants?
https://xspraypharma.com/modular_finance_pressmeddelande/xspray-pharmas-large-shareholders-and-key-individuals-declare-their-intent-to-exercise-to5-warrants-in-november/
Grow up, idiot!
It's confusing. In our 1st quarter 10-Q, Humanigen informed us that, "We have executed a non-binding letter of intent and are engaged in exclusive negotiations relating to a proposed business combination with a privately held biopharmaceutical company (the “Partner Company”). The proposed terms for the business combination contemplate a tax-free stock-for-stock merger, as a result of which we would issue shares of our capital stock to stockholders of the Partner Company which are expected to represent roughly two times the number of our currently outstanding shares of common stock.
pg 14
https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465923007002/hgen-20230331.htm
When Baudax announced the acquisition of Tera-Immune, that, too, "... was structured as a stock-for-stock transaction..."
https://www.baudaxbio.com/news-and-investors/press-releases/detail/267/baudax-bio-acquires-teraimmune-inc
And somewhere along the line, for some reason, I thought we may be looking at a non-US based business combination with a subsidiary of a large Pharma. That was an overwhelming consideration. Look at J&J's subsidiaries, as I did, when I was wondering if we might enter into an agreement with Janssen, one of their subsidiaries. They've got a zillion subsidiaries.
https://www.sec.gov/Archives/edgar/data/200406/000119312512075565/d281803dex21.htm
I would prefer not to think of any type of business affiliation, to be honest. They tend to end up in litigation. I just happen to think that Novavax has more to offer than Baudax, but the question is, how valuable is Tera-Immune?
At the same time, announcing some type of merger or business combination may add fuel to the fire when we announce our loaned shares recall, and that may be the best thing about any structural change to our business. Otherwise, I just want to see management retain control of Humanigen, however we end up structured.
I used to have search capabilities on this platform, yet, even with that, it was often difficult to find information I had previously referenced, where the source of the information was linked. So I can only post what I recall. An example of that concerned the capability for potential use of the Chinese balloon to disperse biological agents. That wasn't new technology. In some US museum, there is a WWII Japanese balloon recovered on our soil that had biological disbursement capability. Another example concerned the number of shares in our float, a reported 229M. I linked the source data in real time, but we no longer have access to that data source.
As long as I have posted, about a broad array of subjects concerning Humanigen, I have tried to have a basis for my comments. But now, it seems you think I'm telling lies about a recall of our loaned shares, and a potential business partnership or merger with Baudax. Again, I've already provided the reasons for my thoughts. You're entitled to express your opinion, if you think my opinion amounts to BS. But a lie is a whole different thing.
It may be a partnership agreement for all I know. But I do think we will see a stock-for-stock transaction.
I am out of my league on this issue, and appreciate the commentary from you and others in this regard.
I truly will not be surprised if we announce the recall of our loaned shares tomorrow. I mentioned previously that I still have one open sell order, which I would LOVE to have filled.
In terms of those of us who want to enter buy orders, or to re-enter our sell orders in the US, we'll have to see if we have a chance to trade on holiday-shortened Friday.
When trading resumes, I expect sellers will be very happy. New buyers? Not so much.
But, that didn't prove to be the case after the first recall of our loaned shares. This time, however, I hope we have positive news that will prevent the full retracement of our share price to the degree seen previously.
An $8B Market Cap, at pre-forward split prices, would equate to ~$67 per share. Divide that price by 5, if management declares a 5:1 forward stock split.
I'm way out on the limb here, partner. But I'm just trying to tell you what I think we could see. I've tried to put myself in management's shoes for so long, I may not be able to look at things any other way, than the way I do.
I haven't even considered that Humanigen would agree to take on Baudax's debt and overhead.
I think management's goal is to help developers provide for a comprehensive cancer treatment line of products derived from state-of-the-art technologies, to include Treg, CAR-T, and Xspray's Hynap technology for CML, to complement our effort with AML. This is already a $2B market for Xspray, and an NDA next year could have added revenue potential, especially if lenz can be effective in enabling nilotinib to cease incurring food interactions, and eliminate the black box warning on their packaging. Lenz could be the "go-to" product for developers bringing these new platforms and therapeutics to market.
https://xspraypharma.com/modular_finance_pressmeddelande/xspray-pharmas-xs003-achieves-superior-bioavailability-milestone-matching-tasigna-at-reduced-dosage/
This is frontier cancer cure territory, and lenz will be interwoven into the process.
Yeah, it's pretty scary to think about what COULD happen. But when our own universities can produce a coronavirus with an 80% kill rate, and when almost 7,000 Chinese men of military age come over the southern border in just one month, AND when the American public becomes complacent about shots that are vaccines in name only, we are poised for disaster.
At the least, we need to be prepared for the worst. We need a true vaccine, which actually helps to prevent the initial infection of covid. I think Humanigen and Novavax have that. And we need a therapeutic that will treat any variant of the virus. Lenz will not only do that, it will program an appropriate immune response to further infections, and hopefully, to reinfections, as well.
I think it is time to harvest the fruits of our effort, not only with Baudax, but with Novavax, as well. And there is opportunity beyond that, as well, with CMML. We have seen movement in all three of the illustrated opportunities.
Actually, Tank, the statement I referenced is really saying that Baudax has requested Confidential Treatment of Information they submitted in their filing. I suspect that information will be in regards to a merger with Humanigen, which WILL move the needle in terms of both allowing the company to leave the Expert Market, and avoid creditors from initiating forced bankruptcies, for both companies.
More importantly, positive news such as this merger will allow the company to announce the recall of their loaned shares THURSDAY, which is not only Thanksgiving, it is also the 8th anniversary of our first recall of loaned shares. Our partial day of trading Friday could have a significant impact on our account balances.
The filing concludes with, "Schedules have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. Baudax Bio agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that Baudax Bio may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished."